DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
6.39
-0.36 (-5.33%)
Aug 28, 2026, 4:00 PM EDT - Market closed
DiaMedica Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 5.13 | 15.65 | 3.03 | 4.54 | 4.73 | 4.71 |
Short-Term Investments | 38.38 | 44.24 | 41.12 | 48.35 | 28.77 | 40.41 |
Cash & Short-Term Investments | 43.5 | 59.89 | 44.15 | 52.9 | 33.5 | 45.11 |
Cash Growth | 44.83% | 35.66% | -16.54% | 57.89% | -25.74% | 64.00% |
Other Receivables | 0.24 | 0.26 | 0.24 | 0.37 | 0.08 | 0.13 |
Receivables | 0.24 | 0.26 | 0.24 | 0.37 | 0.08 | 0.13 |
Prepaid Expenses | 0.57 | 0.48 | 0.23 | 0.41 | 0.21 | 0.08 |
Other Current Assets | - | - | - | - | 0.04 | 0.11 |
Total Current Assets | 44.32 | 60.63 | 44.61 | 53.68 | 33.84 | 45.44 |
Property, Plant & Equipment | 0.29 | 0.34 | 0.43 | 0.49 | 0.56 | 0.11 |
Long-Term Deferred Charges | 0.4 | 0.4 | - | - | - | - |
Other Long-Term Assets | - | - | 1.31 | - | - | - |
Total Assets | 45 | 61.37 | 46.35 | 54.16 | 34.4 | 45.55 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 2.81 | 1.48 | 0.94 | 0.93 | 0.73 | 0.51 |
Accrued Expenses | 3.67 | 3.55 | 4.35 | 1.78 | 1.37 | 0.97 |
Current Portion of Leases | 0.12 | 0.11 | 0.1 | 0.08 | 0.07 | 0.05 |
Total Current Liabilities | 6.59 | 5.13 | 5.39 | 2.79 | 2.17 | 1.52 |
Long-Term Leases | 0.07 | 0.13 | 0.24 | 0.32 | 0.4 | 0 |
Total Liabilities | 6.66 | 5.26 | 5.63 | 3.1 | 2.57 | 1.53 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Additional Paid-In Capital | 231.32 | 228.83 | 180.7 | 166.61 | 128.08 | 126.58 |
Retained Earnings | -192.95 | -172.77 | -140 | -115.56 | -96.18 | -82.5 |
Comprehensive Income & Other | -0.04 | 0.05 | 0.02 | 0.01 | -0.07 | -0.05 |
Shareholders' Equity | 38.34 | 56.11 | 40.72 | 51.06 | 31.83 | 44.02 |
Total Liabilities & Equity | 45 | 61.37 | 46.35 | 54.16 | 34.4 | 45.55 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.19 | 0.24 | 0.34 | 0.4 | 0.47 | 0.05 |
Net Cash (Debt) | 43.32 | 59.65 | 43.81 | 52.5 | 33.03 | 45.06 |
Net Cash Growth | 45.63% | 36.17% | -16.55% | 58.92% | -26.69% | 64.52% |
Net Cash Per Share | 0.83 | 1.27 | 1.08 | 1.61 | 1.25 | 2.17 |
Filing Date Shares Outstanding | 53.93 | 53.88 | 42.86 | 37.96 | 26.46 | 26.44 |
Total Common Shares Outstanding | 53.93 | 53.74 | 42.82 | 37.96 | 26.44 | 26.44 |
Working Capital | 37.72 | 55.5 | 39.22 | 50.89 | 31.67 | 43.92 |
Book Value Per Share | 0.71 | 1.04 | 0.95 | 1.35 | 1.20 | 1.66 |
Tangible Book Value | 38.34 | 56.11 | 40.72 | 51.06 | 31.83 | 44.02 |
Tangible Book Value Per Share | 0.71 | 1.04 | 0.95 | 1.35 | 1.20 | 1.66 |
Machinery | 0.28 | 0.28 | 0.25 | 0.22 | 0.2 | 0.14 |
Leasehold Improvements | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0 |